RU2011139638A - Сублингвальная фармацевтическая композиция, содержащая нейтральное масло - Google Patents
Сублингвальная фармацевтическая композиция, содержащая нейтральное масло Download PDFInfo
- Publication number
- RU2011139638A RU2011139638A RU2011139638/15A RU2011139638A RU2011139638A RU 2011139638 A RU2011139638 A RU 2011139638A RU 2011139638/15 A RU2011139638/15 A RU 2011139638/15A RU 2011139638 A RU2011139638 A RU 2011139638A RU 2011139638 A RU2011139638 A RU 2011139638A
- Authority
- RU
- Russia
- Prior art keywords
- eur
- oil
- composition according
- migliol
- specified
- Prior art date
Links
- 230000007935 neutral effect Effects 0.000 title claims abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 11
- 239000000203 mixture Substances 0.000 claims abstract 24
- 239000003921 oil Substances 0.000 claims abstract 22
- 235000019198 oils Nutrition 0.000 claims abstract 22
- 229940079593 drug Drugs 0.000 claims abstract 10
- 239000003814 drug Substances 0.000 claims abstract 10
- 125000005456 glyceride group Chemical group 0.000 claims abstract 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract 5
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims abstract 3
- 239000002253 acid Substances 0.000 claims abstract 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000003240 coconut oil Substances 0.000 claims abstract 3
- 235000019864 coconut oil Nutrition 0.000 claims abstract 3
- 239000003026 cod liver oil Substances 0.000 claims abstract 3
- 235000012716 cod liver oil Nutrition 0.000 claims abstract 3
- 229940105990 diglycerin Drugs 0.000 claims abstract 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims abstract 3
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical class CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 claims abstract 3
- 239000010685 fatty oil Substances 0.000 claims abstract 3
- 235000021323 fish oil Nutrition 0.000 claims abstract 3
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims abstract 3
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims abstract 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract 3
- 239000003346 palm kernel oil Substances 0.000 claims abstract 3
- 235000019865 palm kernel oil Nutrition 0.000 claims abstract 3
- 235000013311 vegetables Nutrition 0.000 claims abstract 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000006 Nitroglycerin Substances 0.000 claims abstract 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims abstract 2
- 239000004359 castor oil Substances 0.000 claims abstract 2
- 239000002285 corn oil Substances 0.000 claims abstract 2
- 235000005687 corn oil Nutrition 0.000 claims abstract 2
- 238000012377 drug delivery Methods 0.000 claims abstract 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims abstract 2
- 239000010464 refined olive oil Substances 0.000 claims abstract 2
- 239000004094 surface-active agent Substances 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 239000000341 volatile oil Substances 0.000 claims 2
- KRWBMXNBYQFMLZ-HOWIICQTSA-N (6e,10e,14e,18e,22e)-3,7,11,15,19,23,27-heptamethyloctacosa-6,10,14,18,22,26-hexaen-1-ol Chemical compound OCCC(C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C KRWBMXNBYQFMLZ-HOWIICQTSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 229960001391 alfentanil Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229960000981 artemether Drugs 0.000 claims 1
- 229960004191 artemisinin Drugs 0.000 claims 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims 1
- 229930101531 artemisinin Natural products 0.000 claims 1
- 229960002970 artemotil Drugs 0.000 claims 1
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 1
- 229960004991 artesunate Drugs 0.000 claims 1
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 claims 1
- 229950004689 carfentanil Drugs 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 1
- 229950010274 lofentanil Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
- 229960004739 sufentanil Drugs 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- -1 without limitation Chemical compound 0.000 claims 1
- 239000007320 rich medium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2009/050416 WO2010122276A1 (en) | 2009-04-23 | 2009-04-23 | Drug delivery |
| GB0906977A GB2469792A (en) | 2009-04-23 | 2009-04-23 | Oil-based pharmaceutical formulation for sublingual delivery |
| GBPCT/GB2009/050416 | 2009-04-23 | ||
| GB0906977.4 | 2009-04-23 | ||
| PCT/GB2010/050671 WO2010122355A1 (en) | 2009-04-23 | 2010-04-23 | Sublingual pharmaceutical composition comprising a neutral oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011139638A true RU2011139638A (ru) | 2013-05-27 |
Family
ID=42236683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011139638/15A RU2011139638A (ru) | 2009-04-23 | 2010-04-23 | Сублингвальная фармацевтическая композиция, содержащая нейтральное масло |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120058158A1 (enExample) |
| EP (1) | EP2421503A1 (enExample) |
| JP (1) | JP2012524771A (enExample) |
| CN (1) | CN102458358A (enExample) |
| AU (1) | AU2010240653A1 (enExample) |
| BR (1) | BRPI1013539A2 (enExample) |
| CA (1) | CA2756879A1 (enExample) |
| IL (1) | IL215454A (enExample) |
| MX (1) | MX2011010835A (enExample) |
| MY (1) | MY167918A (enExample) |
| NZ (1) | NZ595467A (enExample) |
| RU (1) | RU2011139638A (enExample) |
| SG (1) | SG175160A1 (enExample) |
| WO (1) | WO2010122355A1 (enExample) |
| ZA (1) | ZA201107089B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US20130254139A1 (en) * | 2012-03-21 | 2013-09-26 | Xiaoguang Lei | Systems and methods for building a universal intelligent assistant with learning capabilities |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US10376586B2 (en) * | 2016-02-16 | 2019-08-13 | Entourage Bioscience, LLC | Method and compositions for solubilizing non-polar constituents |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| CN122182527A (zh) | 2016-05-05 | 2026-06-12 | 阿奎斯蒂弗医疗股份有限公司 | 增强递送的肾上腺素组合物 |
| US11273131B2 (en) * | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| CA3048485C (en) * | 2016-12-26 | 2022-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| CN111465391A (zh) * | 2017-09-27 | 2020-07-28 | 阿奎斯蒂弗医疗股份有限公司 | 具有增强的递送的肾上腺素和前药的组合物 |
| US12558305B2 (en) | 2018-12-29 | 2026-02-24 | Solventum Intellectual Properties Company | Oral articles and methods of use |
| US12390488B2 (en) | 2018-12-29 | 2025-08-19 | Solventum Intellectual Properties Company | Oral articles and methods of use |
| WO2021201680A1 (en) | 2020-03-31 | 2021-10-07 | Hasan Djohan | Treatment of hyperinflammatory syndrome |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE71520T1 (de) * | 1986-03-10 | 1992-02-15 | Burghart Kurt | Pharmazeutische zubereitung sowie verfahren zur herstellung derselben. |
| US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| DK1361864T3 (en) * | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| SI1976521T1 (sl) * | 2006-01-25 | 2015-06-30 | Insys Therapeutics, Inc. | Podjezično fentanilno pršilo |
| WO2009020666A1 (en) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Oral cannabinoid liquid formulations and methods of treatment |
| GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
| DK2424523T3 (da) * | 2009-04-23 | 2012-09-24 | Londonpharma Ltd | Sublingual sprayformulering med dihydroartemisinin |
-
2010
- 2010-04-23 CA CA2756879A patent/CA2756879A1/en not_active Abandoned
- 2010-04-23 BR BRPI1013539A patent/BRPI1013539A2/pt not_active Application Discontinuation
- 2010-04-23 US US13/265,825 patent/US20120058158A1/en not_active Abandoned
- 2010-04-23 MY MYPI2011005079A patent/MY167918A/en unknown
- 2010-04-23 EP EP10715336A patent/EP2421503A1/en not_active Withdrawn
- 2010-04-23 NZ NZ595467A patent/NZ595467A/xx not_active IP Right Cessation
- 2010-04-23 AU AU2010240653A patent/AU2010240653A1/en not_active Abandoned
- 2010-04-23 JP JP2012506583A patent/JP2012524771A/ja active Pending
- 2010-04-23 WO PCT/GB2010/050671 patent/WO2010122355A1/en not_active Ceased
- 2010-04-23 RU RU2011139638/15A patent/RU2011139638A/ru unknown
- 2010-04-23 MX MX2011010835A patent/MX2011010835A/es active IP Right Grant
- 2010-04-23 SG SG2011073939A patent/SG175160A1/en unknown
- 2010-04-23 CN CN2010800179717A patent/CN102458358A/zh active Pending
-
2011
- 2011-09-28 ZA ZA2011/07089A patent/ZA201107089B/en unknown
- 2011-10-02 IL IL215454A patent/IL215454A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2756879A1 (en) | 2010-10-28 |
| IL215454A (en) | 2014-11-30 |
| CN102458358A (zh) | 2012-05-16 |
| EP2421503A1 (en) | 2012-02-29 |
| JP2012524771A (ja) | 2012-10-18 |
| ZA201107089B (en) | 2012-12-27 |
| MY167918A (en) | 2018-09-27 |
| US20120058158A1 (en) | 2012-03-08 |
| MX2011010835A (es) | 2012-05-08 |
| IL215454A0 (en) | 2011-12-29 |
| SG175160A1 (en) | 2011-11-28 |
| BRPI1013539A2 (pt) | 2016-04-12 |
| WO2010122355A1 (en) | 2010-10-28 |
| NZ595467A (en) | 2013-08-30 |
| AU2010240653A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524771A5 (enExample) | ||
| JP7621450B2 (ja) | ω３脂肪酸の自己乳化組成物 | |
| US20120058158A1 (en) | Sublingual Pharmaceutical Composition Comprising a Neutral Oil | |
| JP2021107433A (ja) | ω３脂肪酸の自己乳化組成物 | |
| WO2002039983A3 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
| RU2011148140A (ru) | Самомикроэмульгирующаяся оральная фармацевтическая композиция, содержащая гидрофильное лекарственное средство, и способ ее приготовления | |
| NZ600720A (en) | A Seamless Capsule For A Liquid Pharmaceutical Composition | |
| WO2010117873A3 (en) | Progesterone solutions for increased bioavailability | |
| KR20110126746A (ko) | 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용 | |
| JP2013508296A5 (enExample) | ||
| NZ603162A (en) | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | |
| Aggarwal et al. | Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation | |
| RU2015144013A (ru) | Липидные композиции рацекадотрила | |
| RU2012120388A (ru) | Фармацевтические композиции, включающие производное камптотецина | |
| RU2017111503A (ru) | КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| AR084545A1 (es) | Preparacion de absorcion percutanea que contiene rivastigmina | |
| Goswami et al. | Permeation enhancer for TDDS from natural and synthetic sources: A review | |
| RU2015102597A (ru) | Липидные композиции рацекадотрила | |
| RU2013126259A (ru) | Фармацевтическая композиция таксоидов | |
| GB2469792A (en) | Oil-based pharmaceutical formulation for sublingual delivery | |
| ES2971854T3 (es) | Preparación de absorción transdérmica que contiene oxibutinina | |
| HRP20201923T1 (hr) | Farmaceutske formulacije loratadina za kapsuliranje i njihove kombinacije | |
| US20170368023A1 (en) | Sublingual spray formulation comprising dihydroartemesinin | |
| RU2015128028A (ru) | Длинноцепочечные липосбалансированные сложные эфиры тестостерона для пероральной доставки | |
| AR084235A1 (es) | Composiciones farmaceuticas que comprenden alisporivir |